MANCO – Monoclonal Antibodies against COVID-19 – is an EU research project
funded under the Horizon 2020 programme.
The MANCO project is coordinated by the Erasmus Medical Centre (EMC) based in The Netherlands.
The project has started on 1st March 2020 and will last about 3 years.
Project Identity Card
Monoclonal Antibodies against
Grant Agreement N° 101003651
1st March 2020 – 31st May 2023
1st March 2020
31st May 2023
8 partners from
4 Countries :
Spain & France
MANCO is a collaborative research project bringing together a complementary and highly experienced group of 8 partners from 4 European countries (The Netherlands, Germany,
Spain and France) that will achieve the critical mass required to deliver the ambitious objectives of this research programme.
THE OVERALL CONCEPT OF THIS
COLLABORATIVE RESEARCH PROJECT
Overall, The MANCO project aims at contributing to the rapid international response against COVID-19, through preclinical and clinical evaluation of monoclonal antibodies against this coronavirus.
More specifically, MANCO will advance one lead (prophylactic and/ or therapeutic) monoclonal antibody to reach preclinical package completion, by leveraging clinical expertise, infrastructure and relevant network.